Overview

Evaluation of Safety and Efficacy of Nasea(R)/Ramosetron Inj. in Patients Undergoing Facial Bone Fracture Operations

Status:
Terminated
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Postoperative nausea and vomiting (PONV) is one of the most common and distressing complications after anaesthesia and surgery, and may lead to serious postoperative complications This prospective, randomized study designed to evaluate the best injection time to get the prophylactic anti-emetic efficacy of ramosetron, a newly developed 5-HT(3) antagonist in patients undergoing facial bone surgery.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Ramosetron